Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-beta treatment does not elevate cortisol in multiple sclerosis.

A T Reder1, M T Lowy

  • 1Department of Neurology, University of Chicago, IL 60637.

Journal of Interferon Research
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.

Genes and immunity·2013
Same author

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

The pharmacogenomics journal·2012
Same author

Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology.

Neurology·2012
Same author

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Neurology·2012
Same author

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2011
Same author

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

Journal of neurology, neurosurgery, and psychiatry·2010
Same journal

Rapid activation of the interferon-gamma signal transduction pathway by inhibitors of tyrosine phosphatases.

Journal of interferon research·1994
Same journal

Interferon-stimulated response element and NF kappa B sites cooperate to regulate double-stranded RNA-induced transcription of the IP-10 gene.

Journal of interferon research·1994
Same journal

Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.

Journal of interferon research·1994
Same journal

Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2.

Journal of interferon research·1994
Same journal

IDO mutants cross resistant to type I interferon retain p91-dependent gene induction.

Journal of interferon research·1994
Same journal

Interferon-alpha 2 produced by normal human leukocytes is predominantly interferon-alpha 2b.

Journal of interferon research·1994
See all related articles

Interferon-beta (IFN-beta) treatment for multiple sclerosis (MS) does not increase cortisol levels. This suggests that IFN-beta

Area of Science:

  • Neuroimmunology
  • Endocrinology
  • Pharmacology

Background:

  • Interferons (IFN) are utilized in treating cancer and multiple sclerosis (MS).
  • Elevated serum cortisol from high-dose IFN may influence disease progression.
  • IFN-induced cortisol changes could potentially accelerate MS relapse recovery.

Purpose of the Study:

  • To investigate whether interferon-beta (IFN-beta) administration affects serum and urine cortisol levels in patients with multiple sclerosis (MS).
  • To determine if the therapeutic effects of IFN-beta in MS are indirectly mediated by alterations in cortisol levels.

Main Methods:

  • Patients with MS received IFN-beta at doses of 9 or 45 MU every other day.
  • Serum and urine cortisol levels were monitored during the treatment period.

Related Experiment Videos

Main Results:

  • IFN-beta administration at the specified doses did not lead to a significant elevation in either serum or urine cortisol levels in MS patients.
  • No correlation was observed between IFN-beta treatment and changes in cortisol biomarkers.

Conclusions:

  • The clinical efficacy of IFN-beta in managing multiple sclerosis is likely due to direct mechanisms.
  • IFN-beta's therapeutic effects in MS are not indirectly mediated through significant alterations in serum cortisol levels.